Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies
PR Newswire —
NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) following the Company's announcement of topline results from its Phase III Orbit and Cosmic Studies, focusing on the effectiveness of setrusumab (UX143) on...